Cartesian Therapeutics Inc’s recently made public that its Director BARABE TIMOTHY C acquired Company’s shares for reported $0.21 million on Dec 04 ’25. In the deal valued at $6.86 per share,30,000 shares were bought. As a result of this transaction, BARABE TIMOTHY C now holds 54,366 shares worth roughly $0.43 million.
Then, CHRISTOPHER M JEWELL bought 26,935 shares, generating $192,585 in total proceeds.
Before that, SPRINGER TIMOTHY A bought 48,595 shares. Cartesian Therapeutics Inc shares valued at $508,751 were divested by the Director at a price of $10.47 per share. As a result of the transaction, SPRINGER TIMOTHY A now holds 620,175 shares, worth roughly $4.9 million.
Wedbush initiated its Cartesian Therapeutics Inc [RNAC] rating to an Outperform in a research note published on July 09, 2025; the price target was $38. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. TD Cowen began covering RNAC with “Buy” recommendation on August 06, 2024. Oppenheimer revised its rating on July 02, 2024. It rated RNAC as “a Perform” which previously was an “an Outperform”.
Price Performance Review of RNAC
On Tuesday, Cartesian Therapeutics Inc [NASDAQ:RNAC] saw its stock jump 17.56% to $7.9. Over the last five days, the stock has gained 17.73%. Cartesian Therapeutics Inc shares have fallen nearly -65.67% since the year began. Nevertheless, the stocks have fallen -55.89% over the past one year. While a 52-week high of $26.20 was reached on 01/16/25, a 52-week low of $5.98 was recorded on 11/06/25.
Levels Of Support And Resistance For RNAC Stock
The 24-hour chart illustrates a support level at 7.21, which if violated will result in even more drops to 6.51. On the upside, there is a resistance level at 8.50. A further resistance level may holdings at 9.09.
How much short interest is there in Cartesian Therapeutics Inc?
A steep rise in short interest was recorded in Cartesian Therapeutics Inc stocks on 2025-11-14, dropping by 94359.0 shares to a total of 2.03 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 2.12 million shares. There was a decline of -4.65%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 04, 2024 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $50 price target.
